Senhwa Biosciences Inc

Senhwa Biosciences Inc

TTPEX:6492
28.65
TWD
-0.25
(-0.87%)
-3.23EPS
3.93BMarket Cap

Total Valuation

TWD

As of September 30, 2026, Senhwa Biosciences Inc carries a market capitalization of 3.93B, placing it among publicly traded companies globally. Its enterprise value stands at 2.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.93B
Enterprise Value2.57B

Important Dates

Senhwa Biosciences Inc's next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of September 30, 2026, Senhwa Biosciences Inc has 114.39M shares outstanding.

Shares Outstanding114.39M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3,494.75, and the price-to-book ratio stands at 2.84.

PS Ratio3,494.75
PB Ratio2.84
P/TBV Ratio2.84
P/FCF Ratio-12.73
P/OCF Ratio-12.78

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 2,673.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.57B versus a market cap of 3.93B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2,673.37

Financial Position

As of September 30, 2026, Senhwa Biosciences Inc maintains a current ratio of 22.43, meaning it holds 22.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.12, indicating moderate leverage, while an interest coverage ratio of -436.29 demonstrates limited ability to service its debt obligations.

Current Ratio22.43
Quick Ratio21.79
Debt / Equity1.12
Debt / EBITDA-0.05
Interest Coverage-436.29

Financial Efficiency

TWD

Over the twelve months ended September 30, 2026, Senhwa Biosciences Inc posted a negative return on equity (ROE) of -28.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.10, reflecting losses generated across the asset base. The company generates approximately 25,263.16 in revenue per employee across its workforce of 38.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-28.40
Return on Assets (ROA)-27.10
Revenue Per Employee25,263.16
Employee Count38.00

Taxes

TWD

Over the twelve months ended September 30, 2026, Senhwa Biosciences Inc recorded 1.34M in income tax expense. The company reported a pretax loss of -314.07M and -315.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax1.34M

Stock Price Statistics

TWD

As of the close on November 17, 2026, Senhwa Biosciences Inc's stock has declined approximately 28.76% over the past 52 weeks. The 50-day moving average sits at 32.67, while the 200-day moving average is 42.53.

52-Week Price Change-28.76%
50-Day Moving Average32.67
200-Day Moving Average42.53

Income Statement

TWD

Over the twelve months ended September 30, 2026, Senhwa Biosciences Inc generated 960,000.00 in revenue and converted that into -315.41M in net income, yielding earnings per share of -3.23. EBITDA reached -312.38M, while operating income came in at -323.88M.

Revenue960,000.00
Gross Profit445,000.00
Operating Income-323.88M
Pretax Income-314.07M
Net Income-315.41M
EBITDA-312.38M
EBIT-323.88M
Earnings Per Share (EPS)-3.23

Balance Sheet

TWD

As of September 30, 2026, Senhwa Biosciences Inc holds 1.38B in cash and equivalents against 15.49M in total debt, resulting in a net debt position of -1.38B. Total book value stands at 1.38B, with working capital of 1.36B providing operational flexibility.

Cash & Cash Equivalents1.38B
Total Debt15.49M
Net Debt-1.38B
Equity (Book Value)1.38B
Book Value Per Share12.09
Working Capital1.36B

Cash Flow

TWD

Senhwa Biosciences Inc produced -262.59M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -896,000.00 in capital expenditures, free cash flow totaled -263.48M - equivalent to -2.70 per share.

Operating Cash Flow-262.59M
Capital Expenditures-896,000.00
Free Cash Flow-263.48M
FCF Per Share-2.70

Margins

Over the twelve months ended September 30, 2026, Senhwa Biosciences Inc posted a gross margin of 46.35, reflecting its pricing power and cost economics. The operating margin of -33,737.71 and net profit margin of -32,855.10 provide insight into operational efficiency.

Gross Margin46.35
Operating Margin-33,737.71
Pretax Margin-32,715.94
Profit Margin-32,855.10
EBITDA Margin-32,539.90

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -7.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.33, meaning Senhwa Biosciences Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-21.33
FCF Yield-7.85

Stock Splits

Senhwa Biosciences Inc's most recent stock split took place on July 28, 2026 with a 391:403 split ratio.

Last Split Date7/28/2026
Split Ratio391:403

Scores

As of September 30, 2026, Senhwa Biosciences Inc has an Altman Z-Score of 34.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score34.20